Volitionrx limited announces second quarter 2021 financial results and business update

Strong balance sheet with approximately $27.9 million in cash and cash equivalents strengthened the company's veterinary leadership team to drive commercial focus expanded the company's intellectual property portfolio published two clinical papers continued focus on, and made strong progress towards, product launches and licensing in both the human and veterinary spaces worldwide austin, texas, aug. 11, 2021 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition") today announced financial results and a business update for the second quarter ended june 30, 2021. volition management will host a conference call tomorrow, august 12 at 8:00 a.m.
VNRX Ratings Summary
VNRX Quant Ranking